ALBPS — Biophytis SA Share News
0.000.00%
Last trade - 00:00Biophytis: Rises on approval to recruit more patients for COVID-19 treatment study
Biotech group Biophytis to recruit more patients for COVID-19 treatment trial
Brief: Biophytis: Trading Suspension Pending Nasdaq Debut
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM
Brief: Biophytis Announces Public Offering To List On Nasdaq Priced At $16.75/ADS
Brief: Biophytis To Launch Proposed Public Offering, Nasdaq Listing
Brief: Biophytis: Start Of Patient Recruitment For Part 2 Of Phase 2-3 COVA Trial
Brief: Biophytis SA Sees U.S. IPO Of 1.2 Million American Depositary Shares Priced Between $15.00 And $18.00 Per ADS - SEC Filing
Brief: Biophytis Receives DMC Recommendation For Recruitment For Part 2 Of COVA Study
Brief: Biophytis: Last Patient Completes Final Visit In SARA-INT
Brief: Biophytis Updates On Sara-Obs Study Results
Brief: Biophytis : Paris Court of Appeal rules in Biophytis’ favor
Brief: Biophytis Enrolls First Patient in Brazil in COVA
Brief: Biophytis Says First US Patient Enrolled In COVA Study
Brief: Biophytis Announces EUR 10 Million Capital Increase Through Private Placement
Brief: Biophytis H1 Net Loss Narrows To EUR 9.5 Million
Brief: Biophytis Announces Issuance Of EUR 3 Mln Tranche Of ORNANE
Brief: Biophytis Enrolls First Patient In COVA On COVID-19 Related Respiratory Failure
Brief: Biophytis Extends Treatment Period For Sarconeos Study